Australian Nuclear Science and Technology Organisation Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2018
NCT03392428
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Australian Nuclear Science and Technology Organisation | Australian Nuclear Science and Technology Organisation (ANSTO)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5